Journal Article

Activity of Amoxicillin/Clavulanate in Patients with Tuberculosis

Henry F. Chambers, Tanil Kocagöz, Tugrul Sipit, Joan Turner and Philip C. Hopewell

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 4, pages 874-877
Published in print April 1998 | ISSN: 1058-4838
Published online April 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/513945
Activity of Amoxicillin/Clavulanate in Patients with Tuberculosis

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Some β-lactam antibiotics are active in vitro against Mycobacterium tuberculosis. There are anecdotal reports of successful treatment of tuberculosis caused by multiple-drug-resistant strains of M. tuberculosis with regimens that included amoxicillin/clavulanate. Reduction of M. tuberculosis in the sputum of patients with pulmonary tuberculosis during administration of amoxicillin/clavulanate was measured by a quantitative culture method to determine the activity in vivo. Patients were randomized to receive isoniazid, ofloxacin, or amoxicillin/clavulanate for 7 days. Isoniazid was the most effective agent, reducing M. tuberculosis after 2 days at a mean rate (± standard deviation) of 0.60 ± 0.30 log10 cfu/mL per day, compared with 0.32 ± 0.05 and 0.34 ± 0.03 for ofloxacin and amoxicillin/clavulanate, respectively. The early bactericidal activity of amoxicillin/clavulanate was comparable to that reported for antituberculous agents other than isoniazid. Further studies of β-lactam antibiotics with in vitro activity against M. tuberculosis are warranted to define their role in treatment of tuberculosis.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.